Literature DB >> 8615493

Postoperative analgesia with continuous epidural sufentanil and bupivacaine: a prospective study in 614 patients.

A A Broekema1, M J Gielen, P J Hennis.   

Abstract

To assess the efficacy and safety of postoperative analgesia with continuous epidural sufentanil and bupivacaine, we performed a prospective study in 614 patients undergoing major surgery. Before surgical incision, all patients received an initial dose of 50 micrograms sufentanil in 6-10 mL bupivacaine 0.125% via a lumbar or thoracic catheter. After 1 h, a continuous infusion was started with 50 micrograms sufentanil in 50 mL bupivacaine 0.125% at a rate of 6-10 mL/h. The infusion was continued postoperatively for 1-5 days or longer, depending on the type of operation and the patient's analgesic need. In the majority of patients, adequate pain relief was obtained at rest and during movement. Late respiratory depression was observed in three patients; in most patients only minor side effects were seen. Technical complications during epidural puncture or insertion of the catheter were 4% and 3%, respectively. We conclude that continuous epidural sufentanil and bupivacaine is safe and effective.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8615493     DOI: 10.1097/00000539-199604000-00014

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  3 in total

1.  Audit of a ward-based patient-controlled epidural analgesia service in Ireland.

Authors:  T Tan; D Wilson; A Walsh; P Hu; C Power
Journal:  Ir J Med Sci       Date:  2010-11-23       Impact factor: 1.568

Review 2.  Epidural anaesthesia and spinal haematoma.

Authors:  H Wulf
Journal:  Can J Anaesth       Date:  1996-12       Impact factor: 5.063

3.  Patient satisfaction with continuous epidural analgesia after major surgical procedures at a Swedish University hospital.

Authors:  Egidijus Semenas; Michael Hultström
Journal:  PLoS One       Date:  2020-07-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.